Angeion on track to implant Model 2020 ICDs in U.S., Europe by year-end; Sentinel trials on hold.
This article was originally published in The Gray Sheet
Executive Summary
ANGEION MODEL 2020 ICD INITIAL IMPLANTS REMAIN ON SCHEDULE for December despite a suspension of Sentinel series implantable cardioverter defibrillator device implants announced by the company Nov. 12, Angeion President and CEO Whitney McFarlin reported during a same-day teleconference. Clinical development of the 46 cc 2020 ICD will be pursued in the U.S. and Europe, and investigational device exemption and CE Mark approvals are expected before year-end.